Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
Rhea-AI Summary
Quantum BioPharma (NASDAQ: QNTM) has submitted its patented drug candidate Lucid-21-302 (Lucid-MS) to the UK's Innovative Licensing and Access Pathway (ILAP) Passport program. The drug represents a first-in-class treatment for multiple sclerosis, specifically targeting demyelination.
The ILAP program is designed to accelerate the development and approval process of innovative medicines through collaboration between medicine developers, the MHRA, health assessment bodies, NHS, and patients. This submission marks the first step in potentially fast-tracking the drug's development and approval process in the UK.
Positive
- First-in-class treatment targeting demyelination in Multiple Sclerosis
- Potential accelerated development and approval through UK's ILAP program
- Strategic global regulatory approach for efficient clinical development
Negative
- Drug is still in early development stages with no clinical data presented
- No guarantee of ILAP Passport approval or eventual drug success
News Market Reaction – QNTM
On the day this news was published, QNTM gained 5.13%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., the submission of its patented candidate breakthrough drug, Lucid-21-302 (Lucid-MS), to the Innovative Licensing and Access Pathway (ILAP) Passport program in the United Kingdom (UK). The ILAP Passport application was submitted for Lucid-21-302 as a new, first-in-class treatment for multiple sclerosis (MS).
The ILAP Passport is the first step in the UK’s Innovative Licensing and Access Pathway (ILAP) – a program designed to accelerate the pace at which groundbreaking new medicines and treatments reach patients. ILAP brings together all key partners, including medicine developers, the Medicines and Healthcare Products Regulatory Agency (MHRA), health assessment bodies, the National Health System (NHS), and patients themselves. By working together through a single, streamlined platform, ILAP aims to reduce the time it takes to develop, review, approve, and deliver new treatments to patients. This highly coordinated and collaborative approach helps ensure that patients get the earliest possible access to the latest medical innovations, while also supporting the NHS and boosting the UK economy.
“We are excited to complete this submission for an ILAP Passport as this Program will help accelerate the clinical development of Lucid-21-302 as a new treatment for Multiple Sclerosis. Lucid-21-302 represents a new, patented, first-in-class treatment for MS targeting demyelination. We are excited about the possibility that the ILAP Program could accelerate drug development, regulatory approval and, most importantly, patient access to this exciting, new potential MS treatment in the UK,” said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
Dr. Lakshmi P. Kotra, a Director at Quantum Biopharma, commented that “our goal has always been to bring innovative drugs to patients as quickly as possible, and programs such as this in the UK are ideal avenues. At Quantum, we carefully and deliberately follow a well-thought-out global regulatory strategy to advance our clinical development efficiently, and as such we welcome partnerships with all stakeholders for better healthcare.”
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
What is Quantum BioPharma's new drug candidate for Multiple Sclerosis?
What is the UK ILAP Passport program that QNTM has applied for?
How would the ILAP program benefit Quantum BioPharma's MS drug development?
What stage of development is QNTM's Multiple Sclerosis drug currently in?
What makes Lucid-21-302 different from other Multiple Sclerosis treatments?
